Soligenix (SNGX) Stock Overview
A late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
SNGX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Soligenix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.55 |
| 52 Week High | US$6.23 |
| 52 Week Low | US$1.09 |
| Beta | 1.96 |
| 1 Month Change | 25.00% |
| 3 Month Change | -43.43% |
| 1 Year Change | -59.84% |
| 3 Year Change | -99.02% |
| 5 Year Change | -99.61% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Soligenix (NASDAQ:SNGX) Will Have To Spend Its Cash Wisely
Aug 20
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma
Oct 05U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer
Sep 12Soligenix announces $2.6M FDA grant to further study blood cancer candidate
Sep 06Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
Sep 06Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M
Aug 12Soligenix, SERB Pharma team up to develop therapy for ricin poisoning
Jul 25Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
Apr 22Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?
Jan 03Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now
Sep 17Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?
Aug 30Shareholder Returns
| SNGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.9% | 3.1% | 0.5% |
| 1Y | -59.8% | 3.9% | 20.0% |
Return vs Industry: SNGX underperformed the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: SNGX underperformed the US Market which returned 19.8% over the past year.
Price Volatility
| SNGX volatility | |
|---|---|
| SNGX Average Weekly Movement | 28.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SNGX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SNGX's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 15 | Christopher Schaber | www.soligenix.com |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis.
Soligenix, Inc. Fundamentals Summary
| SNGX fundamental statistics | |
|---|---|
| Market cap | US$12.61m |
| Earnings (TTM) | -US$10.36m |
| Revenue (TTM) | n/a |
Is SNGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNGX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.36m |
| Earnings | -US$10.36m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 11:00 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Soligenix, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Keith Markey | Griffin Securities |